➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Merck
Dow

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,200,088


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,200,088
Title:Sulfoalkyl ether cyclodextrin compositions
Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Inventor(s): Antle; Vincent D. (Olathe, KS)
Assignee: Cydex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/789,598
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,200,088
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 9,200,088

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Sedor Pharms Llc SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-001 Nov 5, 2020 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Sedor Pharms Llc SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-002 Nov 5, 2020 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,200,088

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009241858   Get Started Free
Brazil PI0905080   Get Started Free
Canada 2702603   Get Started Free
Canada 2771879   Get Started Free
China 101959508   Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
Moodys
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.